[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634856":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":24,"responsibleParty":31,"collaborators":24,"id":33,"slug":24,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":21,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":24,"enrollmentInfo":41,"targetDuration":24,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":24,"overallStatus":52,"whyStopped":24,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":24},{"fullName":5,"class":6},"Context Therapeutics Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a","EXPERIMENTAL","Dose Escalation-Bayesian Optimal Interval (BOIN) Design with approximately 54 patients in dose escalation.",[13],"Drug: CT-202",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b","Phase 1b: Dose Expansion - participants will be evaluated in 4-6 cohorts at different doses and schedules of CT-202",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","CT-202","Nectin-4 bispecific",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Context Clinical Development","CONTACT","267.225.7416","Cntx-ct202-101@contexttherapeutics.com",{"type":32,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100634856",false,"NCT07545122","A Phase 1a\u002F1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers","A Phase 1a\u002F1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers","Inclusion Criteria:\n\n* Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies\n* Participants with measurable disease per RECIST 1.1\n* ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks\n* Participants have adequate organ function.\n\nExclusion Criteria:\n\n* History of severe skin toxicity\n* Uncontrolled significant active infection or any medical or other condition that in the opinion of the Investigator would preclude the participant's participation in the study.\n* Concurrent participation in another investigational clinical trial.","ALL","18 Years",{"count":42,"type":43},162,"ESTIMATED","INTERVENTIONAL",[46],"PHASE1","This is a Phase 1a\u002F1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory\u002Fresistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.",[49,50,51],"Triple Negative Breast Cancer (TNBC)","Colorectal Cancer","Urothelial Cancer","NOT_YET_RECRUITING","2026-04-16",{"date":55,"type":56},"2026-04-22","ACTUAL",{"date":58,"type":43},"2026-09",{"date":60,"type":43},"2030-01",{"name":5,"class":6}]